WO2001040236A2 - Processus chimiques et intermediaires - Google Patents

Processus chimiques et intermediaires Download PDF

Info

Publication number
WO2001040236A2
WO2001040236A2 PCT/GB2000/004527 GB0004527W WO0140236A2 WO 2001040236 A2 WO2001040236 A2 WO 2001040236A2 GB 0004527 W GB0004527 W GB 0004527W WO 0140236 A2 WO0140236 A2 WO 0140236A2
Authority
WO
WIPO (PCT)
Prior art keywords
isoxazol
oxazolidin
difluorophenyl
yloxymethyl
compound
Prior art date
Application number
PCT/GB2000/004527
Other languages
English (en)
Other versions
WO2001040236A3 (fr
Inventor
Michael Barry Gravestock
Kenneth Edwin Herbert Warren
David Simon Ennis
Angela Charlotte Currie
Debra Ainge
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001540991A priority Critical patent/JP2003515539A/ja
Priority to HU0204052A priority patent/HUP0204052A2/hu
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to MXPA02005396A priority patent/MXPA02005396A/es
Priority to KR1020027007072A priority patent/KR20020058072A/ko
Priority to SK786-2002A priority patent/SK7862002A3/sk
Priority to AU17156/01A priority patent/AU762241B2/en
Priority to EP00979764A priority patent/EP1237895A2/fr
Priority to IL14964100A priority patent/IL149641A0/xx
Priority to CA002395052A priority patent/CA2395052A1/fr
Priority to BR0016087-3A priority patent/BR0016087A/pt
Priority to EEP200200282A priority patent/EE200200282A/xx
Publication of WO2001040236A2 publication Critical patent/WO2001040236A2/fr
Publication of WO2001040236A3 publication Critical patent/WO2001040236A3/fr
Priority to BG106728A priority patent/BG106728A/xx
Priority to IS6401A priority patent/IS6401A/is
Priority to NO20022605A priority patent/NO20022605L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Definitions

  • the invention relates to chemical processes and chemical intermediates. More particularly, it relates to processes and intermediates which are useful in the selective formation of a primary mono-phosphoryl group in a terminal- 1 ,2-diol-propanoyl containing system, most particularly certain oxazolidinone anti-Gram positive bacterial agents containing such functionality.
  • the invention also relates to processes for the manufacture of said intermediates and to processes for the manufacture of such oxazolidinone compounds utilising said intermediates.
  • Co-pending International Patent Application No. GB99/01753 (WO 99/64417) describes a new class of antibacterial oxazolidinone compounds which are effective as anti- Gram positive bacterial agents, and certain processes for their preparation. Of the compounds disclosed, those of the formula (I) are included :
  • HET is a C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S, which ring is optionally substituted on an available carbon atom by 1 or 2 substituents independently selected from (l-4C)alkyl, amino, (l-4C)alkylamino, (1- 4C)alkoxy and halogen, and/or on an available nitrogen atom (provided that the ring is not thereby quaternised) by (l-4C)alkyl;
  • R 2 and R 3 are independently hydrogen or fluoro;
  • Rep is of the formula R 13p CO- (wherein R 13p is (l-lOC)alkyl substituted by two or more hydroxy groups; 2 of which are in a 1,2-diol orientation, ie. there is a terminal primary alcohol with an adjacent secondary alcohol), or pharmaceutically-acceptable salts, or in-vivo- hydrolysable esters thereof.
  • R 13p is (l-lOC)alkyl substituted by two or more hydroxy groups; 2 of which are in a 1,2-diol orientation, ie. there is a terminal primary alcohol with an adjacent secondary alcohol
  • pharmaceutically-acceptable salts or in-vivo- hydrolysable esters thereof.
  • In-vivo hydro lysable esters include compounds of formula (I) and (I-l) in which any free hydroxy group independently forms a phosphoryl ester of the formula (PD3) :
  • those of formula (I-l) are the pharmaceutically active anti-bacterial enantiomer.
  • the pure enantiomer depicted in (I-l), or mixtures of the 5R and 5S enantiomers, for example a racemic mixture are included in GB99/01753. If a mixture of enantiomers is used, a larger amount (depending upon the ratio of the enantiomers) will be required to achieve the same effect as the same weight of the pharmaceutically active enantiomer.
  • the enantiomer depicted below is the 5R enantiomer.
  • the preparation described includes isolation of the primary mono-phosphoryl compound (Intermediate Example 15) from a mixture of compounds (including, for example, the bis- phosphoryl and cyclic phosphoryl compounds) by use of Medium Pressure Liquid Chromatography using ethyl acetate as the eluant.
  • Other compounds of formula (I) and (I-l) above may be prepared using analagous chemistry.
  • the detailed chemistry and reaction conditions employed is described in the accompanying non-limiting Examples, or is within the skill of the ordinary organic/medicinal chemist (see also WO 97/30995, the relevant process sections of which are inco ⁇ orated herein, for details on prepartion of certain intermediates).
  • GB99/01753 discloses that for a compound of formula (I) and (I-l) containing a number of free hydroxy groups, those groups not being converted into a prodrug functionality may be protected (for example, using a t- butyl-dimethylsilyl group), and later deprotected. Also, enzymatic methods may be used to selectively phosphorylate or dephosphorylate alcohol functionalities.
  • the prodrugs containing groups (PD3) may be prepared by reaction of a compound of formula (I) and (I- 1 ) containing suitable hydroxy group/s with a suitably protected phosphorylating agent (for example, containing a chloro or dialkylamino leaving group), followed by oxidation (if necessary) and deprotection.
  • the "Existing Route" to the said compound although satisfactory, is not particularly suitable for the manufacture of large quantities of such products.
  • Selectivity of reaction is important and can impact upon the yield of desired product obtained. Poor selectivity can also lead to the formation of undesired by-products which require removal.
  • the "Existing Route” has potential difficulties associated with the selective formation, in good yield, of the primary mono-phosphoryl/secondary hydroxy moiety.
  • Suitable leaving groups include halo (e.g. iodo, bromo, chloro), triflate or enol phosphate.
  • the protected aniline used as the initial starting material may alternatively be protected as -N-[SiR 3 ] 2 where each R is independently a (l-4C)alkyl group, eg. -N-(SiMe 3 ) 2 .
  • R is independently a (l-4C)alkyl group
  • -N-(SiMe 3 ) 2 we have now discovered a number of further, convenient and useful, processes for the manufacture of said compound (and by analogy other compounds of formula (I) and (I- 1)), which reduces and/or converges the number of reaction stages and, reduces or removes the need for chromatographic purification of intermediates and/or final products.
  • the invention also relates to the application of the chemistry described herein to any system requiring formation of a primary mono-phosphoryl group in a terminal- 1 ,2-diol-propanoyl containing system (such as, for example, 2,3-dihydroxypropanoyl and 3,4-dihydroxy-2-oxo- butyl).
  • a terminal- 1 ,2-diol-propanoyl containing system such as, for example, 2,3-dihydroxypropanoyl and 3,4-dihydroxy-2-oxo- butyl.
  • the invention relates to such 1 ,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l), and most particularly to the said compound.
  • the invention also relates to 1,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l) wherein HET is a C-linked 6-membered heteroaryl ring containing 1 or 2 N, which ring is optionally substituted on any available C atom (provided that when the N atom is adjacent to the link, there is no substitution on any C atom that is adjacent to this N atom) by 1, 2 or 3 substituents independently selected from (l-4C)alkyl, amino, (l-4C)alkylamino, (l-4C)alkoxy, (l-4C)alkoxycarbonyl and halogen.
  • Preferred 6- membered heteroaryl rings are pyridin-2-yl, pyridazin-3-yl or pyrazin-2-yl.
  • the invention also relates to 1,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l) wherein HET is a C-linked 5- or 6-membered heteroaryl ring as described herein, wherein the link to the oxazolidinone ring is via a thiomethyl (-CH 2 - S-) link rather than an oxymethyl (-CH 2 -O-) link (see claim 2 for compounds of formula(I-2)).
  • the invention may also be used in 1 ,2-diol-propanoyl containing systems in a compound of formula (I) and (I-l) wherein HET is a C-linked 5- or 6-membered heteroaryl ring as described in WO 00/21960 (inco ⁇ orated herein by reference), wherein the link to the oxazolidinone ring is via an aminomethyl (-CH 2 -NH 2 -) link.
  • HET is a C-linked 5- or 6-membered heteroaryl ring as described in WO 00/21960 (inco ⁇ orated herein by reference), wherein the link to the oxazolidinone ring is via an aminomethyl (-CH 2 -NH 2 -) link.
  • protecting groups have been referred to.
  • protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons).
  • Protecting groups may be used and removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • the Schemes may be genericised to cover other analogous compounds of formula (I) and (I-l) and (1-2) mentioned herein (see claim 2 for (1-2)). Furthermore, the invention also relates to the application of the chemistry described herein to any system requiring formation of a primary mono-phosphoryl group (-OPO(OH) 2 ) in a terminal- 1 ,2-diol- propanoyl (HO-CH 2 CH(OH)-CO-) containing system.
  • -OPO(OH) 2 a primary mono-phosphoryl group
  • HO-CH 2 CH(OH)-CO- a terminal- 1 ,2-diol- propanoyl
  • a particularly preferred process is that illustrated in Scheme 2B.
  • the use of the hydroxy acid (2H) allows the formation of a protected primary 1 ,2-diol species (PgO- CH 2 CH(OH)-CO-, wherein Pg is a protecting group suitable for protecting alcohols and removable by acid, such as, for example, t-butyl, as in Compound (21) in the case of the said compound).
  • Pg is a protecting group suitable for protecting alcohols and removable by acid, such as, for example, t-butyl, as in Compound (21) in the case of the said compound.
  • the secondary phosphoryl compound which may be optionally protected, for example in the form of a phosphate ester, such as the t-butyl ester as in Compound (2J) in the case of the said compound).
  • the secondary phosphoryl compound is in the form of a phosphate ester.
  • a secondary phosphoryl compound suitable for use in the process may be obtained, for example, by standard phosphorylation chemistry, for example as described herein, using tert-butyl tetraethylphosphorodiimidite, or using phosphorous oxychloride or
  • Scheme 3C is particularly preferred, and offers the advantageous use of the hydroxy acid (2H) to give the protected primary alcohol, and then selective secondary phosphorylation to give (3D); followed by coupling, and then by deprotection of the protected primary alcohol & predominant rearrangement of the secondary phosphoryl compound to the primary phosphoryl compound.
  • Scheme 3C offers a particularly favourable route to the said compound, comprising comparatively few reaction stages in a convergent fashion.
  • the coupling reaction of Schemes 3A to 3D may be carried out in the presence of a suitable base, for example, nBuLi at ca.
  • a suitable inert solvent or diluent such as, for example, dimethylsulphoxide, 1 ,2-dimethoxyethane, tetrahydrofuran (THF), tetrahydropyran, diglyme or toluene.
  • a preferred solvent is a mixture of THF and toluene.
  • Schemes 3 A to 3D may also be achieved via Grignard chemistry, using, for example, an appropriate 4-bromo-phenyl compound in place of (IF).
  • the starting materials for the reactions described herein may be obtained as described herein, or by analogy to such methods, or by standard procedures of organic chemistry.
  • Intermediates (IE) and (IF) are preferred intermediates, especially (IF). 2.
  • a leaving group other than Br could also be used.
  • allyl alcohol could be used and the substitution performed in a reverse sense to that shown with a leaving group (e.g. chloro or mesylate) on (IB).
  • Nosylate and mesylate may also be used in place of tosylate in the epoxide (IH- 1). Preferably nosylate is used.
  • Example 1 shows retention of stereochemistry, i.e. (R)- and (S)-glycidyl nosylate give, respectively, (R)-, (S)- glycidyl ether product.
  • the other epoxide isomer may be used as a starting material. If a racemate is obtained, chiral resolution/chromatography may be used to obtain the desired isomer.
  • DIPEA is di-isopropyl-ethylamine.
  • non-bulky protecting groups in place of t-Bu may be used in (2G) and (2H), for example, any (l-4C)alkyl group; any silyl group (for example trimethylsilyl); or a benzyl group (e.g. using acid catalysed removal, or a reductive removal using e.g. hydrogenation).
  • (2F) may be converted at ambient temperature to, for example, the disodium salt by treatment with 2 mol.eq. sodium carbonate and working-up in acetone and then IMS. 5.
  • (IK) may be prepared as shown in the Existing Route Scheme or as described in
  • Example 4 hereinafter, in which, for example, Intermediate Example 2 may be prepared as follows :-
  • a solution of 3,5-difluoroaniline in THF is chilled to -70°C.
  • a solution of n-butyl lithium in toluene is added and chlorotrimethylsilane then added to complete the bis- trimethylsilyl protection of 3,5-difluoroaniline.
  • a solution of n-butyl lithium in toluene is added to the chilled solution and a solution of l-benzyl-4-piperidone in toluene then added whilst maintaining the temperature.
  • a solution of aqueous hydrochloric acid is added.
  • the aqueous layer of the alcohol intermediate (Intermediate Example 1) is separated and heated to reflux while simultaneously distilling out tetrahydrofuran to complete the formation of Intermediate
  • Example 2 The reaction is then diluted with water and butanol before adjusting the pH with aqueous ammonia at 40°C. The aqueous layer is separated and discarded. Cyclohexane is added to the organic phase to precipitate the product, which is then filtered off after cooling to ambient temperature, washed with a butanol/cyclohexane mixture, cyclohexane and dried under vacuum.
  • Intermediate Example 4 may be prepared as described in Example 4 hereinafter, or using a solution of n-butyl lithium in toluene.
  • (21) may be converted to Diol (2D) by deprotection, for example using acid conditions, such as HCl/dioxan.
  • Hydrogen peroxide may be used in place of mCPBA in the conversion of (21) to
  • reaction is performed in a suitable solvent, such as dioxan.
  • R includes (l-4C)alkyl, for example, methyl, ethyl, propyl, iso-propyl, butyl, iso- butyl, tert-butyl; hydrogen and benzyl.
  • (l-4C)alkyl includes both straight-chain and branched-chain alkyl groups.
  • references to individual alkyl groups such as
  • the lithiated compound may be transmetallated with, for example titanium chloride, titanium i-propoxide or cerium chloride at a tempertaure of about -30°C. Such transmetallation restricts enolisation of the piperidinone and so aids reaction at the desired centre.
  • (3B) may be prepared from (2B) - see scheme 2A - using standard chemistry.
  • (2H) may be prepared from O-t-Bu-serine (2G) using standard chemistry - see
  • DMF is N,N-dimethylformamide
  • DMA is
  • Mobile phase A 10 mM ammonium acetate pH 4.5.
  • Mobile phase B 10 mM ammonium acetate pH 4.5 in 90% acetonitrile.
  • MIBK - DMF, acetone, toluene, MeCN, DME, NMP, THF, EtOAc, TBME, EtOH, MeOH.
  • the following bases have also been used in the coupling reaction in place of caesium carbonate:- NaH, K 2 CO 3 , NaOH, NaOMe, NaOEt, KOMe, KOEt, KO'Bu, LDA, NEt 3 , NBu 3 , NPr 2 Et.
  • 3-Hydroxyisoxazole may be prepared by cyclisation of CH ⁇ C-CO-NHOH (prepared from CH ⁇ C-CO-O-(l-4C)alkyl) as described in Chem.Pharm.Bull. Japan, 14, 92, (1966).
  • 3-Hydroxyisoxazole may also be prepared as follows :- Hydroxylamine hydrochloride is neutralised with sodium hydroxide to liberate the free base. Ethyl propiolate in EtOH is then added dropwise maintaining the reaction temperature at 20-25°C and the reaction stirred before gradually warming to 50-55°C. Heating is continued at 50-55°C for 2.5h and the reaction is then acidified to pH ⁇ 3 with cone. HC1. On complete addition ca. 90% of the ethanol in the reaction is removed by distillation and the residue extracted with warm toluene. Toluene is removed by distillation to precipitate 3- hydroxyisoxazole, and the precipitation is completed by addition of cyclohexane. The resulting suspension is cooled and filtered prior to the material being dried in vacuo at ambient temperature.
  • hydroxylamine hydrochloride is neutralised with sodium hydroxide.
  • the hydroxylamine free base is reacted with a solution of ethyl propiolate in THF at 55 °C.
  • the reaction mixture is cooled and acidified with hydrochloric acid, and the resulting solution extracted with butyronitrile, washed with dilute hydrochloric acid and the organic solution concentrated under reduced pressure to remove ethanol, THF and water.
  • the solution may be used directly in a next stage.
  • N-benzyloxycarbonyl-3,5-difluoroaniline intermediate is prepared by reaction of
  • reaction mixture was cooled to 20-25 °C, and was washed with H 2 O (20 mL).
  • the organic layer was separated, dried (MgSO 4 ) and was concentrated to give crude product that was purified by flash chromatography to give the desired product (IJ) (1.5g, 53 %).
  • Mobile phase A 0.1% TFA in water.
  • Mobile phase B 0.1% TFA in 90 % MeCN.
  • Toluene - MIBK, THF, Toluene, TBME.
  • HPLC showed 56% conversion to l-[4-(l-benzyl- l,2,3,6-tetrahydro-pyridin-4-yl)-3,5-difluoro-phenylamino]-3-(isoxazol-3-yloxy)-propan-2-ol (with reference to an external standard isolated in another reaction, which may be prepared by hydrolysis of Compound (IJ)).
  • HPLC retention time (see below) 2.1 min.
  • Mobile phase A 0.1% TFA in water.
  • Mobile phase B 0.1% TFA in 90 % MeCN.
  • THF was cooled to -70°C under nitrogen and 8.80ml of 1.6M nBuLi in hexanes (14.08mmol) added dropwise at the same temperature. After 20 minutes at the same temperature a solution of (R)-glycidyl butyrate (2.00g, 13.88mmol in 5ml THF) was added dropwise and the mixture stirred for 30 minutes at -70°C, and then stirred to ambient temperature overnight.
  • Example 4 (2.6g, 6.5mmol), 3-hydroxyisoxazole (see Example 1; 0.60g, 7.06mmol), triphenylphosphine (1.96g, 7.48mmol) and diisopropylazodicarboxylate (1.44g, 7.13mmol) in THF (40ml) were reacted using the general method of Example 1.
  • the resultant product was purified by flash chromatograpy (Merck 9385 silica, EtOAc / isohexane (3:2) eluant initially, then repeated using methyl tert-butylether eluant) to give the title product (2.6g, 86%) as a gum.

Abstract

L'invention porte sur des processus chimiques et des intermédiaires chimiques s'avérant efficaces pour la formation sélective d'un groupe mono-phosphoryle primaire (-OPO(OH2)) dans un système à terminaison 1,2-diol-propanoyl (HO-CH2CH(OH)-CO-), et sur des processus chimiques et des intermédiaires chimiques (et leurs procédés d'obtention) s'avérant particulièrement efficaces pour la préparation d'agents d'oxazolidinone anti bactéries Gram positifs présentant une telle fonctionnalité, et en particulier pour la préparation de 5(R)-isoxazol-3-yloxyméthyl-3-(4-(1-(2(S)-hydroxy-3-phosphoryl-propanoyl)-1,2,5,6-tétrahydropyridy-4-yl)-3,5-difluorophényl)oxazolidin-2-one.
PCT/GB2000/004527 1999-12-03 2000-11-28 Processus chimiques et intermediaires WO2001040236A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002395052A CA2395052A1 (fr) 1999-12-03 2000-11-28 Processus chimiques et intermediaires
IL14964100A IL149641A0 (en) 1999-12-03 2000-11-28 Chemical processes and intermediates
MXPA02005396A MXPA02005396A (es) 1999-12-03 2000-11-28 Proceso e intermedios quimicos.
HU0204052A HUP0204052A2 (hu) 1999-12-03 2000-11-28 Kémiai eljárások és közbenső termékek
SK786-2002A SK7862002A3 (en) 1999-12-03 2000-11-28 Method of formation of a primary mono-phosphoryl group in a terminal 1,2-diol-propanoyl function group and intermediates used at this method
AU17156/01A AU762241B2 (en) 1999-12-03 2000-11-28 Chemical processes and intermediates
BR0016087-3A BR0016087A (pt) 1999-12-03 2000-11-28 Processo para a formação de um grupo de mono-fosforila primária em uma funcionalidade de 1,2-diol-propanóila terminal, processos para a preparação de 5-(het-x-metil)-3-(4-(1-benzil-1,2,5,6-tetraidropirid-4-il)- 3,5-difluorofenil)oxazolidin-2-ona, e de 5-isoxazol-3-iloximetil-3-(4-(1-benzil-1,2,5,6-tetraidrop irid-4-il)-3,5-difluorofenil)oxazolidin-2-ona, e, composto intermediário quìmico
JP2001540991A JP2003515539A (ja) 1999-12-03 2000-11-28 化学的方法および中間体
KR1020027007072A KR20020058072A (ko) 1999-12-03 2000-11-28 화학방법 및 중간체
EP00979764A EP1237895A2 (fr) 1999-12-03 2000-11-28 Processus chimiques et intermediaires
EEP200200282A EE200200282A (et) 1999-12-03 2000-11-28 Keemilised meetodid ja vaheühendid
BG106728A BG106728A (en) 1999-12-03 2002-05-20 Chemical methods and intermediate compounds
IS6401A IS6401A (is) 1999-12-03 2002-05-28 Efnafræðilegar aðferðir og milliefni
NO20022605A NO20022605L (no) 1999-12-03 2002-05-31 Kjemiske fremgangsmåter og mellomprodukter

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928499.4A GB9928499D0 (en) 1999-12-03 1999-12-03 Chemical processes and intermediates
GB9928499.4 1999-12-03

Publications (2)

Publication Number Publication Date
WO2001040236A2 true WO2001040236A2 (fr) 2001-06-07
WO2001040236A3 WO2001040236A3 (fr) 2002-05-10

Family

ID=10865576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004527 WO2001040236A2 (fr) 1999-12-03 2000-11-28 Processus chimiques et intermediaires

Country Status (22)

Country Link
EP (1) EP1237895A2 (fr)
JP (1) JP2003515539A (fr)
KR (1) KR20020058072A (fr)
CN (1) CN1433421A (fr)
AR (1) AR026700A1 (fr)
AU (1) AU762241B2 (fr)
BG (1) BG106728A (fr)
BR (1) BR0016087A (fr)
CA (1) CA2395052A1 (fr)
CO (1) CO5271712A1 (fr)
CZ (1) CZ20021912A3 (fr)
EE (1) EE200200282A (fr)
GB (1) GB9928499D0 (fr)
HU (1) HUP0204052A2 (fr)
IL (1) IL149641A0 (fr)
IS (1) IS6401A (fr)
MX (1) MXPA02005396A (fr)
NO (1) NO20022605L (fr)
PL (1) PL364762A1 (fr)
SK (1) SK7862002A3 (fr)
WO (1) WO2001040236A2 (fr)
ZA (1) ZA200203876B (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096916A1 (fr) * 2001-06-01 2002-12-05 Astrazeneca Ab Processus de phosphorylation
US6919329B2 (en) 2002-02-25 2005-07-19 Pharmacia & Upjohn Company N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives
US6969726B2 (en) 2003-06-03 2005-11-29 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
US7022705B2 (en) 2001-10-25 2006-04-04 Astrazeneca Ab Isoxazoline derivatives useful as antimicrobials
US7094900B2 (en) 2002-08-12 2006-08-22 Pharmacia & Upjohn Company Llc N-Aryl-2-oxazolidinones and their derivatives
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
US7141570B2 (en) 2002-11-21 2006-11-28 Pharmacia & Upjohn Company N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7141588B2 (en) 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7199143B2 (en) 2002-02-28 2007-04-03 Astrazeneca Ab Chemical compounds
US7304050B2 (en) 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
US7335753B2 (en) 2002-09-26 2008-02-26 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
WO2008038092A2 (fr) 2006-09-25 2008-04-03 Wockhardt Research Centre Pipéridinophényloxazolidinones substituées
US7396847B2 (en) 2001-09-11 2008-07-08 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
US8202843B2 (en) 2004-02-27 2012-06-19 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
US8399660B2 (en) 2005-06-08 2013-03-19 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064417A2 (fr) * 1998-06-05 1999-12-16 Astrazeneca Ab Composes chimiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064417A2 (fr) * 1998-06-05 1999-12-16 Astrazeneca Ab Composes chimiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUCHWALD S.L.: "Stereochemical evidence for pseudorotation in the reaction of a phosphoric monoester" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 106, no. 17, 1984, XP002162618 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US ISSN: 0002-7863 *
KIS K.: "Biosynthesis of riboflavin." BIOCHEMISTRY., vol. 34, no. 9, 1995, pages 2883-2892, XP002162619 AMERICAN CHEMICAL SOCIETY. EASTON, PA., US ISSN: 0006-2960 *
MEYERHOF O.: "]ber die Isolierung der isomeren Phosphoglycerins{uren." BIOCHEMISCHE ZEITSCHRIFT., vol. 276, 1936, pages 239-253, XP000989557 SPRINGER, BERLIN., DE ISSN: 0366-0753 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096916A1 (fr) * 2001-06-01 2002-12-05 Astrazeneca Ab Processus de phosphorylation
US7396847B2 (en) 2001-09-11 2008-07-08 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
US7022705B2 (en) 2001-10-25 2006-04-04 Astrazeneca Ab Isoxazoline derivatives useful as antimicrobials
US6919329B2 (en) 2002-02-25 2005-07-19 Pharmacia & Upjohn Company N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7645781B2 (en) 2002-02-25 2010-01-12 Pfizer Inc N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7141588B2 (en) 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
US7199143B2 (en) 2002-02-28 2007-04-03 Astrazeneca Ab Chemical compounds
US7094900B2 (en) 2002-08-12 2006-08-22 Pharmacia & Upjohn Company Llc N-Aryl-2-oxazolidinones and their derivatives
US7335753B2 (en) 2002-09-26 2008-02-26 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
US7141570B2 (en) 2002-11-21 2006-11-28 Pharmacia & Upjohn Company N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7456206B2 (en) 2003-06-03 2008-11-25 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
US8895741B2 (en) 2003-06-03 2014-11-25 Melinta Therapeutics, Inc. Process for the synthesis of biaryl oxazolidinones
US7148219B2 (en) 2003-06-03 2006-12-12 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
US7705026B2 (en) 2003-06-03 2010-04-27 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
US9550783B2 (en) 2003-06-03 2017-01-24 Melinta Therapeutics, Inc. Biaryl heterocyclic compounds and methods of making and using the same
US6969726B2 (en) 2003-06-03 2005-11-29 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
US7304050B2 (en) 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
US8202843B2 (en) 2004-02-27 2012-06-19 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
US8841263B2 (en) 2004-02-27 2014-09-23 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
US9376400B2 (en) 2005-06-08 2016-06-28 Melinta Therapeutics, Inc. Process for the synthesis of triazoles
US8399660B2 (en) 2005-06-08 2013-03-19 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles
US8796465B2 (en) 2005-06-08 2014-08-05 Melinta Therapeutics, Inc. Process for the syntheses of triazoles
WO2008038092A3 (fr) * 2006-09-25 2009-08-27 Wockhardt Research Centre Pipéridinophényloxazolidinones substituées
US8288416B2 (en) 2006-09-25 2012-10-16 Wockhardt Ltd. Substituted piperidinophenyl oxazolidinones
WO2008038092A2 (fr) 2006-09-25 2008-04-03 Wockhardt Research Centre Pipéridinophényloxazolidinones substituées
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9937192B2 (en) 2012-07-18 2018-04-10 Spero Trinem, Inc. Combination therapy to treat mycobacterium diseases

Also Published As

Publication number Publication date
JP2003515539A (ja) 2003-05-07
IL149641A0 (en) 2002-11-10
GB9928499D0 (en) 2000-02-02
CN1433421A (zh) 2003-07-30
WO2001040236A3 (fr) 2002-05-10
CZ20021912A3 (cs) 2002-08-14
ZA200203876B (en) 2003-08-15
EE200200282A (et) 2003-06-16
AU762241B2 (en) 2003-06-19
CO5271712A1 (es) 2003-04-30
BR0016087A (pt) 2002-08-06
AU1715601A (en) 2001-06-12
EP1237895A2 (fr) 2002-09-11
CA2395052A1 (fr) 2001-06-07
IS6401A (is) 2002-05-28
SK7862002A3 (en) 2003-02-04
AR026700A1 (es) 2003-02-26
NO20022605L (no) 2002-06-26
NO20022605D0 (no) 2002-05-31
PL364762A1 (en) 2004-12-13
BG106728A (en) 2003-02-28
HUP0204052A2 (hu) 2003-03-28
MXPA02005396A (es) 2002-11-29
KR20020058072A (ko) 2002-07-12

Similar Documents

Publication Publication Date Title
AU762241B2 (en) Chemical processes and intermediates
JP7030749B2 (ja) 不斉補助基
US8470987B2 (en) Protective group for synthesis of RNA and derivative
US6617339B1 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
FR3037958A1 (fr)
JPH08301869A (ja) ヘテロ原子−含有ベンゾシクロペンタン−オキサゾリジノン
PL183512B1 (pl) Przeciwbakteryjne fenylooksazolidynony
KR20050106064A (ko) 항생제로서 유용한 히드록시메틸 치환 디히드로이속사졸유도체
KR20010085887A (ko) 항균제로서의 헤테로시클릭 아미노 메틸옥사 졸리디논
EP3560925B1 (fr) Nouveau composé et sel pharmaceutiquement acceptable de celui-ci
US20210317159A1 (en) Alkoxyphenyl derivatives, protected nucleosides and protected nucleotides, method for producing oligonucleotides, and method for removing substituents
JP2008500318A (ja) 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
MXPA06013540A (es) Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
WO2002096916A1 (fr) Processus de phosphorylation
JPH09500131A (ja) Ｈｉｖプロテアーゼ阻害剤の製造方法
JPH10506621A (ja) ジヌクレオチド及びオリゴヌクレオチドアナログのための中間体
WO2004048370A1 (fr) Composes antibacteriens
JP2006520774A (ja) 抗菌性１，３−オキサゾリジン−２−オン誘導体
JP2006520775A (ja) 抗菌性オキサリジノン類

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 149641

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/03876

Country of ref document: ZA

Ref document number: 200203876

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 17156/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000979764

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 106728

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00641/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 519083

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2395052

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005396

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2002-1912

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020027007072

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 540991

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 7862002

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2002 2002117647

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027007072

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008187355

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2002-1912

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000979764

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000979764

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 17156/01

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: PV2002-1912

Country of ref document: CZ